When the COVID-19 pandemic struck in early 2020, doctors and researchers rushed to find effective treatments, and since developing new drugs takes time, there was little of it to spare. In the short term, the most expedient option was to repurpose existing drugs. The subject drew the interest of Caroline Uhler, a computational biologist in MIT's Department of Electrical